United States - English - NLM (National Library of Medicine)

cipla usa inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: -   with urinary retention [see warnings and precautions (5.2)] , -   with gastric retention [see warnings and precautions (5.3)] , -   with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and -   who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin - urologicals, drugs for urinary frequency and incontinence - symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin - urologicals, drugs for urinary frequency and incontinence - symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

United States - English - NLM (National Library of Medicine)

ethex corporation - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol succinate 90 mg - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris. metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (nyha class ii or iii) heart failure of ischemic, hypertensive, or cardiomyopathic origin. it was studied in patients already receiving ace inhibitors, diuretics, and, in the majority of cases, digitalis. in this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemak

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

rebel distributors corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin ethylsuccinate 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susce

United States - English - NLM (National Library of Medicine)

stat rx usa - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan succinate 100 mg - sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan succinate tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of sumatriptan succinate tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets . ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia.